Related Experiment Video
Updated: Nov 6, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Anticoagulation after heart valve replacement]
Frederik Voss1, Christoph Sucker2,3, Jens Litmathe4
1Herzzentrum Trier/Abteilung für Rhythmologie, Krankenhaus der Barmherzigen Brüder, Nordallee 1, 54292, Trier, Deutschland. f.voss@bk-trier.de.
Insights
Patients with mechanical heart valves require anticoagulation with vitamin K antagonists (VKA). Non-vitamin K antagonists (NOAC) are contraindicated, but this review covers anticoagulation for various valve replacements and clinical scenarios.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Context:
- Mechanical heart valve replacement necessitates lifelong anticoagulation to prevent thrombotic and thromboembolic events.
- Current guidelines restrict oral anticoagulation in this population to vitamin K antagonists (VKA).
- Non-vitamin K dependent oral anticoagulants (NOAC) are contraindicated in patients with mechanical heart valves.
Purpose:
- To review current anticoagulation strategies for patients with mechanical heart valve replacement.
- To discuss coagulation inhibition following bioprosthetic or percutaneous valve replacement.
- To provide recommendations for antithrombotic medication in various clinical scenarios for patients with mechanical heart valves.
Summary:
- This review focuses on anticoagulation management in patients with mechanical heart valves, emphasizing the exclusive role of VKAs.
- It also addresses anticoagulation after bioprosthetic or percutaneous valve procedures.
- Evidence-based recommendations for antithrombotic therapy in diverse clinical situations are presented.
Impact:
- Provides critical guidance for clinicians managing anticoagulation in patients with prosthetic heart valves.
- Highlights the limitations of NOACs in mechanical heart valve patients.
- Aims to optimize antithrombotic strategies, reducing thromboembolic risks and improving patient outcomes.
Abstract:
In patients after mechanical heart valve replacement anticoagulation is required for the prevention of thrombotic and thromboembolic events. In this setting oral anticoagulation can only be performed with vitamin K antagonists (VKA), while currently all available non-vitamin K dependent oral anticoagulants (NOAC) are contraindicated in patients with mechanical heart valve replacement. This review deals with anticoagulation in patients with mechanical heart valve replacement as well as coagulation inhibition after bioprosthetic or percutaneous valve replacement. In addition, recommendations are given for antithrombotic medication in patients with mechanical heart valve replacement in various clinical scenarios.
More Related Videos
12:17Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Aortic Regurgitation III: Medical Management
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis IV: Nursing Management